TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04700410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
Study: NCT06026943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaRT seeds insertion
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study: NCT05137288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron , atropine and bupivacaine
Description: Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) .
Study: NCT04906421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: Oral dose, tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose, tablet
Study: NCT06079567

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of new COMs for FSHD2 patients
Description: Monitoring of commonly used and new COMs in FSHD2 patients
Study: NCT05061550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous route.
Study: NCT05061550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive Oleclumab via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive Monalizumab via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0171
Description: Participants will receive AZD0171 via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin as chemotherapy
Study: NCT05285618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argus II
Description: Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.
Study: NCT05061550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Carboplatin/Paclitaxel, as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Carboplatin/Paclitaxel, as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Carboplatin/Paclitaxel, as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Carboplatin/Paclitaxel, as chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Carboplatin/Paclitaxel, as chemotherapy
Study: NCT05626374

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Case Management
Description: Usual case management support during 12-week training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Case Management plus Distress Tool
Description: Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
Study: NCT05061550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Participants will receive Volrustomig via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Participants will receive Rilvegostomig via intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Participants will receive Rilvegostomig via intravenous route.
Study: NCT06523660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHUCK CHUCK SKILLS: CHild's Understanding of Cognitive sKills
Description: The intervention will consist of an online EF training that will be delivered across 10 sessions (one 1 hour session per week for ten weeks). It will target core EF components including inhibitory control, attention shifting, and working memory in children with Autism Spectrum Disorder aged 5 to 7 years. It will also provide strategies (e.g., behavioral principles, compliance training) for promoting behavioral regulation and emotion regulation in these children. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Psychoeducation
Description: Group-based parent psychoeducation, which consists of 10 sessions, 1-hour weekly program delivered via telehealth, will be provided to the control group.
Study: NCT06422910

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)
Study: NCT04891783

Intervention type: DEVICE
Intervention: ultrasonography
Description: The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .

Intervention type: DEVICE
Intervention: ultrasonography
Description: The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .

Intervention type: DEVICE
Intervention: ultrasonography
Description: The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
Study: NCT05486858

Intervention type: OTHER
Intervention: MSK ultrasonograpy
Description: MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.

Intervention type: OTHER
Intervention: MSK ultrasonograpy
Description: MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.

Intervention type: OTHER
Intervention: sitting Functional and Lateral Reach Test
Description: Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.

Intervention type: OTHER
Intervention: sitting Functional and Lateral Reach Test
Description: Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
Study: NCT06199531

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Study: NCT06277921

Intervention type: PROCEDURE
Intervention: Elective Surgery for gastric cancer
Description: Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Intervention type: PROCEDURE
Intervention: Elective Surgery for gastric cancer
Description: Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach
Study: NCT05124652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Adjusting Prosthesis
Description: Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Adjusting Prosthesis
Description: Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
Study: NCT05350930

Intervention type: OTHER
Intervention: Assessment of patient satisfaction regarding tele-consultation
Description: Questionnaire completed following the teleconsultation, if applicable.

Intervention type: OTHER
Intervention: Literacy questionnaire
Description: Questionnaire completed during hospitalization for the first chemotherapy cycle

Intervention type: OTHER
Intervention: Collection of socio-demographic characteristics
Description: Questionnaire completed during patient hospitalization for the first chemotherapy cycle

Intervention type: OTHER
Intervention: Assessment of patient knowledge on chemotherapy side effects and support medications
Description: Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy

Intervention type: OTHER
Intervention: Assessment of patient satisfaction on pharmaceutical follow-up
Description: Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
Study: NCT04842292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Nebulized heparin 25,000 units every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% every 6 hours
Study: NCT06468436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Esketamine Combination
Description: For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1.
Study: NCT04890912

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionation
Description: Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
Study: NCT05704621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: secondary cytoreductive surgery
Description: Maximum effort cytoreductive surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]
Study: NCT06238141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral writing
Description: According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
Study: NCT05069714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX-hold
Description: Temporary discontinuation of methotrexate for 1 or 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX-hold
Description: Temporary discontinuation of methotrexate for 1 or 2 weeks
Study: NCT06229431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Carer Support Needs Assessment Tool Intervention (CSNAT-I)
Description: The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan.
Study: NCT06225895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: patients will receive general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: patients will receive general anesthesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: general anesthesia
Description: patients will receive general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: a rhomboid intercostal nerve block
Description: patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of bupivacaine 0.25%
Study: NCT05192499

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool test
Description: At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool test
Description: At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Induced sputum
Description: At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
Study: NCT04890912

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.